MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER:

2000 ◽  
pp. 1124-1129 ◽  
Author(s):  
DONALD L. LAMM &NA; &NA; ◽  
BRENT A. BLUMENSTEIN ◽  
JOHN D. CRISSMAN ◽  
JAMES E. MONTIE ◽  
JAMES E. GOTTESMAN ◽  
...  
Author(s):  
Vikram M. Narayan

This study summarizes the landmark study assessing the value of maintenance intravesical Bacillus Calmette Guerin (BCG) to reduce the risk for recurrence or progression of high-grade superficial or carcinoma in situ (CIS) transitional cell carcinoma of the bladder. The trial randomized patients with completely resected noninvasive urothelial cell carcinoma at high risk of recurrence to BCG induction alone versus BCG induction plus maintenance therapy in the form of six weekly treatments. The study found that maintenance BCG reduces disease-specific recurrence and may also reduce the rate of disease progression.


2003 ◽  
Vol 169 (3) ◽  
pp. 938-942 ◽  
Author(s):  
SHAHROKH F. SHARIAT ◽  
JA-HONG KIM ◽  
GUSTAVO E. AYALA ◽  
KIMBERLY KHO ◽  
THOMAS M. WHEELER ◽  
...  

2003 ◽  
Vol 169 (4) ◽  
pp. 1541-1545 ◽  
Author(s):  
YOHEI HORIKAWA ◽  
KOKICHI SUGANO ◽  
MASANORI SHIGYO ◽  
HIDENOBU YAMAMOTO ◽  
MASAAKI NAKAZONO ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document